Top 15 Best-Selling Drugs of 2018
Below is GEN’s top 15 list of best-selling prescription drugs in 2018. Sales for most treatments grew despite recent concerns over rising prices. Top-selling drugs are ranked based on sales or revenue reported for 2018 by bio/pharma companies in press announcements, annual reports, investor materials, and/or conference calls. Each drug is listed by name, sponsor(s), 2018 sales, 2017 sales, and the percentage change between both years. See who made the list:
#15. Lyrica®
Pfizer
2018 Sales: $4.970B
2017 Sales: $5.065B
% Change: –1.9%
#14. Stelara
Janssen Biotech (Johnson & Johnson)
2018 Sales: $5.156B
2017 Sales: $4.011B
% Change: 28.5%
#13. Prevnar 13® / Prevenar 13®
Pfizer
2018 Sales: $5.802B
2017 Sales: $5.601B
% Change: 3.6%
#12. Remicade®
Johnson & Johnson and Merck & Co.
2018 Sales: $5.908B
2017 Sales: $7.152B
% Change: –17.4%
#11. Eylea®
Bayer and Regeneron Pharmaceuticals
2018 Sales: $6.551B
2017 Sales: $5.830B
% Change: 12.4%
#10. Xarelto®
Bayer and Johnson & Johnson
2018 Sales: $6.589B
2017 Sales: $6.234B
% Change: 5.8%
#9. Rituxan® (also sold as MabThera)
Roche (Genentech) and Biogen
2018 Sales: $6.750B
2017 Sales: $7.298B
% Change: –7.5%
#8. Avastin®
Roche (Genentech)
2018 Sales: $6.847B
2017 Sales: $6.686B
% Change: 2.4%
#7. Herceptin®
Roche (Genentech)
2018 Sales: $6.981B
2017 Sales: $7.013B
% Change: –0.5%
#6. Enbrel®
Amgen and Pfizer
2018 Sales: $7.126B
2017 Sales: $7.885B
% Change: –9.6%
#5. Keytruda®
Merck & Co.
2018 Sales: $7.171B
2017 Sales: $3.809B
% Change: 88.3%
#4. Opdivo®
Bristol-Myers Squibb and Ono Pharmaceutical
2018 Sales: $7.570B
2017 Sales: $5.763B
% Change: 31.4%
#3. Revlimid
Celgene
2018 Sales: $9.685B
2017 Sales: $8.187B
% Change: 18.3%
#2. Eliquis®
Bristol-Myers Squibb and Pfizer
2018 Sales: $9.872B
2017 Sales: $7.395B
% Change: 33.5%
#1. Humira®
AbbVie
2018 Sales: $19.936B
2017 Sales: $18.427B
% Change: 8.2%
